<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Borrás-Blasco, Joaquín</style></author><author><style face="normal" font="default" size="100%">Valcuende-Rosique, Alejandro</style></author><author><style face="normal" font="default" size="100%">Cornejo-Uixeda, Silvia</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Real-World Persistence on Tofacitinib in Psoriatic Arthritis Patients With Enthesitis: Comments on Recent Findings</style></title><secondary-title><style face="normal" font="default" size="100%">The Journal of Rheumatology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2025-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">1067-1068</style></pages><doi><style  face="normal" font="default" size="100%">10.3899/jrheum.2025-0722</style></doi><volume><style face="normal" font="default" size="100%">52</style></volume><issue><style face="normal" font="default" size="100%">10</style></issue><abstract><style  face="normal" font="default" size="100%">To the Editor:We read with interest the recent article by Braña et al1 evaluating the persistence and safety of tofacitinib (TOF) under real-world conditions in a refractory population of patients with psoriatic arthritis (PsA), with a special focus on the enthesitis phenotype. Their findings provide valuable insight into the retention profile of TOF in a population largely underrepresented in randomized controlled trials. We would, however, like to comment on one methodological aspect that merits further discussion: the lack of adherence data in the analysis of treatment persistence.1Though the authors define persistence as time from treatment initiation to discontinuation and analyze this outcome using robust survival techniques, they do not incorporate any formal measurement of adherence.1 This distinction is critical because persistence and adherence, though related, represent distinct constructs.2 Persistence refers to the length of time a patient continues treatment without … Address correspondence to Dr. J. Borrás-Blasco, Pharmacy Department, Hospital de Sagunto, Avda Ramon y Cajal, s/n Sagunto 46520, Valencia, Spain. Email: jborrasb{at}gmail.com.</style></abstract></record></records></xml>